European Neuropsychopharmacology最新文献

Placental epigenetic signatures of maternal distress in glucocorticoid-related genes and newborn outcomes: A study of Spanish primiparous women 糖皮质激素相关基因中孕产妇痛苦的胎盘表观遗传学特征与新生儿结局：对西班牙初产妇的研究。

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.001

{"title":"Placental epigenetic signatures of maternal distress in glucocorticoid-related genes and newborn outcomes: A study of Spanish primiparous women","authors":"","doi":"10.1016/j.euroneuro.2024.10.001","DOIUrl":"10.1016/j.euroneuro.2024.10.001","url":null,"abstract":"<div><div>Maternal stress during pregnancy can impact offspring health, increasing the risk of neuropsychiatric disorders. The human placenta plays a crucial role in understanding this effect, influencing fetal programming as it connects maternal and fetal circulation. Our hypothesis centers on maternal stress influencing children's outcomes through placental DNA methylation, targeting three cortisol-regulating genes: <em>NR3C1, FKBP5</em>, and <em>HSD11B2</em>.</div><div>In this pilot study, chorionic villi and maternal decidua placental layers from 45 mother-infant dyads (divided into two groups based on high/low maternal stress exposure) were analyzed for DNA methylation at the genes of interest via targeted bisulfite sequencing. Pregnant women provided four saliva samples throughout a day for cortisol determinations and were assessed for the presence of depressive symptoms at each of the three trimesters of pregnancy. Newborns underwent neurodevelopmental assessments and salivary cortisol evaluations at 7 weeks.</div><div>Increased maternal diurnal cortisol levels in the first trimester of pregnancy was significantly associated with elevated DNA methylation at exon 1D of the <em>NR3C1</em> gene and lower DNA methylation at intron 7 of the <em>FKBP5</em> gene, both in chorionic villi samples. Elevated DNA methylation at introns 1 and 7 of <em>FKBP5</em> in the maternal decidua were strongly linked to an anticipated delivery. DNA methylation at the <em>HSD11B2</em> promoter region was uniformly low across all placental samples. No associations with newborn neurodevelopment were found.</div><div>These results emphasize the importance of exploring layer-specific methylation differences at distinct pregnancy stages, highlighting the complex interplay between maternal stress, placental epigenetic modifications, and fetal development throughout the prenatal period.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The microRNA profile of brain-derived extracellular vesicles: A promising step forward in developing pharmacodynamic biomarkers for psychiatric disorders 脑源性细胞外囊泡的 microRNA 图谱：在开发精神疾病药效学生物标记物方面迈出充满希望的一步

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.002

{"title":"The microRNA profile of brain-derived extracellular vesicles: A promising step forward in developing pharmacodynamic biomarkers for psychiatric disorders","authors":"","doi":"10.1016/j.euroneuro.2024.10.002","DOIUrl":"10.1016/j.euroneuro.2024.10.002","url":null,"abstract":"<div><div>MicroRNAs (miRNAs) have the potential to affect drug metabolism, and some drugs affect cellular miRNA expression. miRNAs are found inside extracellular vesicles (EVs), and the profile of these EV-miRNAs can change across different diseases and disease states. Consequently, in recent years EV-miRNAs have attracted increasing attention as possible non-invasive biomarkers. For example, analyzing the miRNA expression profile of brain-derived EVs in blood may allow us to non-invasively assess miRNA dysregulation and thus to gain knowledge about the pathophysiology of psychiatric disorders and identify potential new predictive targets. We searched PubMed for all studies related to the effects of psychiatric medications on EV-miRNAs and identified 14 relevant articles. Taken together, findings indicate that certain EV-miRNAs may be targets for psychiatric medications and that antipsychotics such as olanzapine and antidepressants such as fluoxetine may alter the expression levels of particular EV-miRNAs. If confirmed and replicated, these findings may lead to the suggested miRNA profiles being used as pharmacodynamic biomarkers. However, heterogeneities and uncertainties remain regarding the role of EV-miRNAs in psychiatric disorders and their interaction with neuronal gene expression and drugs. This minireview summarizes some of the findings on the effects of psychiatric medications on EV-miRNAs and describes the potential role of EV-miRNAs as pharmacodynamic biomarkers for psychiatric disorders.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A meta-analysis of data-driven cognitive subgroups in bipolar disorder 双相情感障碍认知分组数据荟萃分析

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.008

{"title":"A meta-analysis of data-driven cognitive subgroups in bipolar disorder","authors":"","doi":"10.1016/j.euroneuro.2024.10.008","DOIUrl":"10.1016/j.euroneuro.2024.10.008","url":null,"abstract":"<div><div>The delineation of cognitive subgroups of bipolar disorder (BD) might be helpful for identifying biologically valid subtypes of this disorder. This meta-analysis identified peer-reviewed literature on studies investigating cognitive subgroups of BD with data-driven clustering methods. Relevant studies were searched in PubMed, Scopus, and Web of Science. Random-effects meta-analysis was performed using R software. A total of 14 cross-sectional studies including euthymic or mildly symptomatic patients with BD were included in the current meta-analysis. The available studies have consistently supported a 3-cluster solution. The pooled prevalence of the severe-impairment, moderate-impairment, and major good-functioning groups were 23.1 % (95%CI, 18.5 %–27.7 %), 42.5 % (95%CI, 36.3 %–48.8 %), and 33.5 % (95%CI, 25.9 %–41.1 %) respectively. Compared to healthy controls, both the severe-impairment (g=−1.40 to −1.73) and moderate-impairment groups (g=−0.59 to −0.96) had significant deficits in all six cognitive domains (verbal memory, visual memory, executive functions, working memory, attention and processing speed). The good-performance subgroup had a small increase in the performance of executive functions (g=0.23) and normal functioning in all other domains. Compared to the good-performance subgroup, the severe-impairment subgroup was characterized by more severe functional impairment, more hospital admissions, a higher percentage of type I BD and antipsychotic use. The characteristics of the moderate-impairment subgroup were lying between the other two subgroups for most of the measures. The current findings support the existence of 3 cognitive subgroups in BD including severe-impairment and moderate-impairment groups which are associated with a more severe course of illness.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“The role of gut microbiota in adult attention deficit hyperactivity disorder: Insights and implications” "肠道微生物群在成人注意缺陷多动障碍中的作用：见解和影响"

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.09.008

引用次数: 0

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.010

引用次数: 0

Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area 口服一水肌酸对抑郁症认知行为疗法的疗效和安全性：在资源匮乏地区进行的为期 8 周的双盲、随机、安慰剂对照可行性和探索性试验。

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-11-01 DOI: 10.1016/j.euroneuro.2024.10.004

{"title":"Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area","authors":"","doi":"10.1016/j.euroneuro.2024.10.004","DOIUrl":"10.1016/j.euroneuro.2024.10.004","url":null,"abstract":"<div><div>Pre-clinical and clinical evidence proposes that creatine monohydrate, an affordable nutraceutical, could be a useful adjunct to conventional antidepressant treatments. In this pilot feasibility and exploratory study, we investigate the 8-week effects of creatine in addition to cognitive-behavioural therapy (CBT) versus placebo plus CBT in depression. For the primary efficacy outcome of change in Patient Health Questionnaire-9 depression score at study endpoint, we used mixed-model repeated measures analysis of covariance. Logistic regressions were employed to assess acceptability (any-cause dropouts), tolerability (dropouts for adverse events), and safety (patients experiencing one or more adverse events). We calculated effect sizes adjusted for age, sex, and baseline depression score. One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression (mean PHQ-9 = 17.6 ± 6.3) were randomised to either creatine+CBT (<em>N</em> = 50) or placebo+CBT (<em>N</em> = 50). At 8 weeks, PHQ-9 scores were lower in both study arms, but significantly more so in participants taking creatine (mean difference= -5.12). Treatment discontinuations due to any cause and to adverse events, and proportion of participants with at least one adverse event were comparable between study arms. This hypothesis-generating trial suggests that creatine could be a useful and safe supplement to CBT for depression. Longer and larger clinical trials are warranted.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does 18 Hz deep TMS benefit a different subgroup of depressed patients relative to 10 Hz rTMS? The role of the individual alpha frequency 与 10 赫兹经颅磁刺激相比，18 赫兹深部经颅磁刺激是否能使不同亚组的抑郁症患者受益？个体阿尔法频率的作用

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-10-12 DOI: 10.1016/j.euroneuro.2024.09.007

{"title":"Does 18 Hz deep TMS benefit a different subgroup of depressed patients relative to 10 Hz rTMS? The role of the individual alpha frequency","authors":"","doi":"10.1016/j.euroneuro.2024.09.007","DOIUrl":"10.1016/j.euroneuro.2024.09.007","url":null,"abstract":"<div><div>Both 10 Hz repetitive transcranial magnetic stimulation (rTMS) as well as 18 Hz deep TMS (dTMS) constitute effective, FDA-approved TMS treatment protocols for depression. However, not all patients experience sufficient symptom relief after either of these protocols. Biomarker-guided treatment stratification could aid in personalizing treatment and thereby enhancing improvement. An individual alpha frequency (iAF)-based EEG-biomarker, Brainmarker-I, can differentially stratify patients to depression treatments. For instance, an iAF close to 10 Hz was associated with better improvement to 10 Hz rTMS, possibly reflecting entrainment of endogenous oscillations to the stimulation frequency.</div><div>Accordingly, we examined whether 18 Hz dTMS would result in better improvement in individuals whose iAF lies around 9 Hz, a harmonic frequency of 18 Hz.</div><div>Curve fitting and regression analyses were conducted to assess the relation between iAF and improvement. For treatment stratification purposes, correlations with iAF-distance to 10 Hz compared 18 Hz dTMS (<em>N</em> = 114) to 10 Hz rTMS (<em>N</em> = 72).</div><div>We found a robust quadratic effect, indicating that patients with an iAF around 9 Hz exhibited least symptom improvement (r<sup>2</sup>=0.126, <em>p</em><.001). Improvement correlated positively with iAF-distance to 10 Hz (<em>p</em>=.003). A secondary analysis in 20 Hz figure-of-eight data confirmed this direction. A significant interaction of iAF-distance and stimulation frequency between 10 and 18 Hz datasets emerged (<em>p</em>=.026).</div><div>These results question entrainment of endogenous oscillations by their harmonic frequency for 18 Hz, and suggest that 10 Hz and 18 Hz TMS target different subgroups of depression patients. This study adds to iAF stratification, augmenting Brainmarker-I with alternative TMS protocols (18 Hz/20 Hz) for patients with a slower iAF, thereby broadening clinical applicability and relevance of the biomarker.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142417138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UPDATE FROM THE “PEDIGREE-BASED WHOLE GENOME SEQUENCING OF AFFECTIVE AND PSYCHOTIC DISORDERS" CONSORTIUM 基于谱系的情感障碍和精神障碍全基因组测序 "的最新进展联合会

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-10-01 DOI: 10.1016/j.euroneuro.2024.08.082

引用次数: 0

TRACKING THE LONGITUDINAL COURSE IN YOUNG PEOPLE AT HIGH RISK OF BIPOLAR DISORDER 追踪躁郁症高危青少年的纵向病程

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-10-01 DOI: 10.1016/j.euroneuro.2024.08.019

{"title":"TRACKING THE LONGITUDINAL COURSE IN YOUNG PEOPLE AT HIGH RISK OF BIPOLAR DISORDER","authors":"","doi":"10.1016/j.euroneuro.2024.08.019","DOIUrl":"10.1016/j.euroneuro.2024.08.019","url":null,"abstract":"<div><div>Young people with a first-degree relative with bipolar disorder (BD) have a 10-15% risk of developing this illness, but currently we have little understanding of the specific clinical and/or biological features which predict such an outcome. Our group in Sydney established the Bipolar Disorder Kids and Sibs high-risk cohort over a decade ago (with 170 high risk young people, 130 controls and 65 who had already developed BD) and have collaborated closely with the US multi-site consortium led by John Nurnberger. We have followed this Australian sample regularly over time, with particular interest in neuroimaging, genetic (including epigenetic), neuropsychological and clinical findings. We have scanned subjects on 3 occasions (baseline, 2 and 10 years), having already published on changes over the first two years. We reported significant weakening in the high-risk subjects of structural connectivity in a network encompassing the left inferior and middle frontal areas, left striatal and thalamic structures, the left fusiform, and right parietal and occipital regions. These findings were more pronounced in those who had developed a first episode of hypo(mania) over those two years. We have also explored for clinical predictors of hypo(mania) onset, finding particular depressive features to be a strong predictor of this outcome. We will present clinical and biological findings of our 10-year follow-up. More studies of long-term biological and clinical changes over time, and predictors of the onset of hypo(mania) are needed to enable rational development of early intervention studies in those at increased familial risk of BD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DRUG REPOSITIONING ANALYSIS IDENTIFIED HUNDREDS OF NOVEL COMPOUNDS ASSOCIATED WITH TOBACCO USE DISORDER 药物重新定位分析发现了数百种与烟草使用障碍有关的新型化合物

IF 6.1 2区医学

European Neuropsychopharmacology Pub Date : 2024-10-01 DOI: 10.1016/j.euroneuro.2024.08.097

引用次数: 0